December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

14.53 +1.00 (+7.39%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces $150 Million Private Placement
From Vor Biopharma
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
VOR Shares Rally Over 40%In Pre-Market Trade After JPMorgan Initiates Bullish Coverage ↗
Via Stocktwits
News headline image
What's going on in today's pre-market session ↗
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch ↗
The Dow Jones futures were up by 0.11% while the S&P 500 futures were up 0.04%. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. ↗
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial ↗
Vor Biopharma prices $100 million share offering as partner RemeGen reports strong Phase 3 results for telitacicept in IgA nephropathy. 
Via Benzinga
News headline image
US Stocks Mixed; Sea Shares Gain After Q3 Results ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Tuesday's pre-market session. ↗
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
From Vor Biopharma
Via GlobeNewswire
News headline image
These stocks are moving in today's after hours session ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗
Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026. 
Via Benzinga
News headline image
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
From Vor Biopharma
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.